The Lab-on-a-chip and Microarrays (Biochip) Market, estimated at USD 22,203.5 Mn in 2025, is expected to exhibit a CAGR of 13.43% and reach USD 53,643.5 Mn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Among type, lab-on-a-chip segment held dominant position in the global lab-on-a-chip and microarrays (biochip) market in 2022, accounting for 72.4% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.
Market Trends:
Technological advancements is one of the key trends expected to propel the growth of the global lab-on-a-chip and microarrays (biochip) market. A lab-on-a-chip could enable healthcare providers to open up diagnosis to a wider population and provide appropriate treatment to those who really need it, without the use of rare and expensive drugs. Moreover, players in the market as well as several governments worldwide are increasingly investing in lab-on-a-chip, as this technology is expected to change daily lives people over the forecast period. This trend is expected to continue over the forecast period, driving the growth of the market.
Competitive Landscape:
Major players operating in the global lab-on-a-chip and microarrays (biochip) market are Merck KgaA, QIAGEN NV, BioMérieux, Illumina Inc., Micronit BV, PerkinElmer Inc., Thermo Fisher Scientific, Fluidigm Corporation, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Abbott Laboratories, Phalanx Biotech Group, and Danaher Corporation (Cepheid), among others.
Recent Developments:
In January 2021, LexaGene aimed to bring its MiQLab from research-only use to point-of-care use to detect the SARS-CoV-2 virus. Emergency use authorization (EUA) would add a rapid test with the accuracy of polymerase chain reaction (PCR).
In March 2020, Veredus Laboratories announced that its product had received CE-IVD marking of VereCoV Detection Kit for commercial launch in Europe.
In December 2019, Dolomite Microfluidics launched a number of new microfluidic chip options for its innovative Telos system. The expanded range now includes a 50 μm version of the Telos 2 Reagent Chip to complement the original 100 μm option, allowing the formation of monodisperse, 10 to 75 μm droplets containing two reagents.
Contact Us